Prevention of infection in critically ill patients by selective decontamination of the digestive tract.
OBJECTIVE
To determine whether selective decontamination of the digestive tract using oral and nonabsorbable antimicrobial agents and parenteral cefotaxime prevents infection in critically ill patients.


METHODS
Randomized, controlled trial without blinding.


METHODS
Surgical trauma and medical intensive care units in a tertiary referral hospital.


METHODS
One hundred fifty patients admitted to surgical trauma and medical intensive care units during a 3-year interval, whose condition suggested a prolonged stay (greater than 3 days).


METHODS
Patients were randomly allocated to an experimental group (n = 75) that received cefotaxime, 1 g intravenously every 8 hours for the first 3 days only, and oral, nonabsorbable antibiotics (gentamicin, polymyxin, and nystatin by oral paste and oral liquid) for the entire stay in the intensive care unit. Control patients (n = 75) received usual care.


METHODS
The number of infections, total hospital days, and deaths, as well as the number of days in intensive care unit, were recorded.


RESULTS
Control patients experienced more infections (36 compared with 12, P = 0.04), including bacteremias (14 compared with 4, P = 0.05) and pulmonary infections (14 compared with 4, P = 0.03). Although total hospital days, days in intensive care, and the overall death rate all were lower in the treatment group, these differences were not statistically significant. Clinically important complications of selective decontamination of the digestive tract were not encountered.


CONCLUSIONS
Selective decontamination of the digestive tract decreases subsequent infection rates, especially by gram-negative bacilli, in selected patients during long-term stays in the intensive care unit.
Cockerill
F R
FR
Mayo Clinic, Rochester, Minnesota.
Muller
S R
SR
Anhalt
J P
JP
Marsh
H M
HM
Farnell
M B
MB
Mucha
P
P
Gillespie
D J
DJ
Ilstrup
D M
DM
Larson-Keller
J J
JJ
Thompson
R L
RL
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003422:Critical Care / Q000379:methods*; D003428:Cross Infection / Q000517:prevention & control*; D004064:Digestive System / Q000382:microbiology*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009960:Oropharynx / Q000382:microbiology; D012007:Rectum / Q000382:microbiology
D000900:Anti-Bacterial Agents